Navesh Sharma
Radiation Oncology · York, PANPI 1124268859
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Sirtex Medical Inc accounts for 98.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $34,699 and has fallen 79.9% since, to $6,965 in 2025. Among radiation oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $804.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sirtex Medical Inc$105K
- Isoray, Inc$900
- Sanofi$135
- Siemens Medical Solutions USA, Inc.$43
- Novartis$37
- AbbVie$36
- plus $171 from 10 others
Across 3 payments — averaging $9749.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$29K
What the payments were for
- Consulting fees$23,52522%
- Speaking & faculty fees$62,00058%
- Travel & lodging$17,63017%
- Food & beverage$3,0093%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sirtex Medical Inc | 115 | $104,840 |
| Isoray, Inc | 1 | $900 |
| Sanofi | 1 | $135 |
| Siemens Medical Solutions USA, Inc. | 1 | $43 |
| Novartis | 1 | $37 |
| AbbVie | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| AstraZeneca | 1 | $19 |
| Varian Medical Systems, Inc. | 1 | $17 |
| Seagen Inc. | 1 | $17 |
| Boston Scientific | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $14 |
| Focal Therapeutics, Inc. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIR-Spheres Microspheres$102,589
- Brachytherapy Source$900
How this compares
$106,163 in reported general payments places this provider in the 95th percentile of 339 radiation oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Insulin Glargine-Yfgn | 13 | $448 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in York
- Chirag ShahPittsburgh$344K
- Neil TaunkPhiladelphia$203K
- Wenyin ShiPhiladelphia$119K
- Zachary HornePittsburgh$56K
- Yvonne MoweryPittsburgh$55K
- Kevin NeadPhiladelphia$50K
- Adam DickerPhiladelphia$46K
- Ajay BhatnagarHershey$42K
- Tinatin ChabrashviliPhiladelphia$39K
- Bryan PukenasPhiladelphia$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.